Long-term remission in schizophrenia and related psychoses with long-acting risperidone: Results obtained in an open-label study with an observation period of 18 months

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 1, 2008, Pages 14-22

  Llorca, P M ^a   Sacchetti, E ^b   Lloyd, K ^c   Kissling, W ^d   Medori, R ^e  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d Outpatient Clinic for Neurology and Psychiatry   (Germany)

^e Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

Injectable; Long acting; Remission; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOZAPINE; CYAMEMAZINE; DIAZEPAM; LONG ACTING DRUG; LORAZEPAM; NEUROLEPTIC AGENT; RISPERIDONE; ZOPICLONE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; BODY MASS; CLINICAL PROTOCOL; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PARKINSONISM; PATIENT COMPLIANCE; PATIENT MONITORING; PSYCHOSIS; RELAPSE; REMISSION; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY; TREMOR; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 38349078233     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46014     Document Type: Article

References (25)

1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27: 596-601.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
3. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005; l62: 441-449.
4. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 200l; 62: 231-238.
5. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006; 67: 575-583.
6. Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf. 2007; 30: 93-105.
7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415-1428.
8. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003; 64: 1250-1257.
9. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006; 67 (Suppl 5): 9-14.
10. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003a; 160: 1125-1132.
11. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003b; 64 (Suppl 12): 5-19.
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276.
13. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001; 62: 92-100.
14. Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, Llorca PM. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol. 2005; 19 (Suppl 5): 15-21.
15. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry. 2004; 19: 219-225.
16. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005; 77: 215-227.
17. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006; 67 (Suppl 5): 3-8.
18. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry. 2006; 39: 161-170.
19. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223.
20. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004; 65: 1084-1089.
21. Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition
22. to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005; 20: 121-130.
23. Schooler NR. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry. 2006; 67 (Suppl5): 19-23.
24. van Os J, Drukker M, á Campo J, Meijer J, Bak M, Delespaul P. Validation of remission criteria for schizophrenia. Am J Psychiatry. 2006a; 163: 2000-2002.
25. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM. Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica. 2006b; 113: 91-95.